Manohar Katakam | Chief Executive Officer
SteroTherapeutics

Manohar Katakam, Ph.D. is a biotech and pharmaceutical leader with over two decades of experience building companies, advancing novel therapies, and delivering measurable shareholder value. His entrepreneurial leadership includes founding and scaling multiple life sciences ventures. As President & CEO of Sterotherapeutics LLC, he drives strategy, fundraising, and global execution for innovative therapies targeting rare and underserved diseases, including a lead candidate for Cushing’s syndrome with proven safety and mechanism of action. Previously, as President & CEO at Makindus Inc., he managed to develop a sterile ocular therapy for Stargardt’s disease to Phase 3 ready. As Co-Founder and Scientific Advisor at Nutherapeutics Pvt Ltd, he helped achieve Asia’s first manufacturing and marketing license for fast-disintegrating thin film formulations. His corporate leadership spans senior roles at major global pharmaceutical companies. At Pfizer, he led multi-region manufacturing expansions, risk mitigation, and technology transfers to ensure uninterrupted vaccine supply to WHO and emerging markets. Earlier, at Aventis Behring, he provided technical and compliance leadership for sterile fill/finish operations in the US and EU. At Centocor, a Johnson & Johnson company, he developed monoclonal antibody formulations for Remicade and transferred to commercial manufacturing sites. Recognized for securing high-value partnerships, negotiating multimillion-dollar cost savings, and navigating complex global manufacturing and regulatory landscapes, Dr. Katakam is an inventor on multiple international drug delivery patents. He holds a Ph.D. and M.S. in Pharmaceutics from Auburn University, an M.S. in Pharmaceutical Technology from Andhra University, and a B.S. in Pharmacy from Kakatiya University.